Two pharmaceutical companies may have a potential breakthrough treatment for Alzheimer's with a new drug.

The drug is called Lecanemab.

An 18-month trial, showed it slowed the progress of the disease by 27%, compared to those who received a placebo.

The companies will apply for regulatory approval of the drug in the U.S. by the end of the year.